Navigation Links
MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
Date:4/12/2011

eatment  
  • There was no statistical difference in PASP between the LEVADEX and placebo groups over two hours
  • No significant electrocardiogram (ECG) changes were observed
  • Adverse events were more frequent in the IV DHE group than in the LEVADEX or placebo groups

  • The three additional LEVADEX related presentations are:
    Utility of LEVADEX (MAP0004) in Situations Where Early Intervention Paradigm Is Impractical
    Session Info: Platform Session: April 12, 2011, 3:00-4:30 p.m. HAST
    Presentation Info: April 12, 2011 at 3:45 p.m. HAST
    Presentation #: 004

    This presentation has been selected by the Scientific Program Subcommittee to be in the top five percent of the American Academy of Neurology presentations and, as such, LEVADEX will be highlighted by the Subcommittee during the Scientific Program Highlights Plenary Session on Friday, April 15, 5:15 – 6:15 p.m.

    The Major Metabolite of Dihydroergotamine (DHE) after Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacologic Activity
    Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
    Poster #: 272

    Migraine Recurrence Rates: Case for Standardization of the Definition
    Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
    Poster #: 285

    About LEVADEX® LEVADEX is an investigational acute drug for migraine that has completed Phase 3 clinical development.  In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler.  LEVADEX contains a novel formulation of dihydroergotamine (DHE).  LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm.  In the Phase 3 trial, patients taking LEVADEX had statistically significant improvement at two hours compared to patients on placebo fo
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
    (Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
    (Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
    Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
    ... HAIKOU, China, May 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Pharma ... Pharma" or the "Company"), a leading fully-integrated specialty pharmaceutical ... Financial Officer, Mr. Frank Waung, has been invited to ... in New York City on May 17, 2011. Conference ...
    ... China, May 13, 2011 /PRNewswire-Asia/ -- Winner Medical Group ... leading manufacturer of medical dressings, medical disposables and non-woven ... today announced it will attend the Oppenheimer 5th Annual ... NY. Winner Medical will present on Tuesday, May 17th ...
    Cached Medicine Technology:China Pharma Holdings, Inc. to Present at the Eighth Annual Piper Jaffray China Growth Conference in New York on May 17, 2011 2Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference 2Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference 3
    (Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
    (Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
    (Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
    (Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
    (Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
    Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
    ... Efficient Operation for Gateway Healthcare , , PROVIDENCE, ... announced today that it is addressing the complex ... with the unique, next generation voice product, Cox Business ... its telecommunications services from a competitive provider to Cox ...
    ... marrow registry is free June 8-22; The Jeff Gordon Foundation seeds ... , MINNEAPOLIS, June 8 Every day, thousands of people ... Registry for a bone marrow match. To highlight the enormous need ... , the new name for the National Marrow Donor Program(R) Registry, ...
    ... ... market today, is now available to more doctors and health care professionals in Missouri through ... ... non-invasive and oral-based lead testing product in the market today, is now available to more ...
    ... ... sensors sizes up to 1.3 - inch format. , ... Van Nuys, CA (PRWEB) June 8, 2009 -- Schneider Optics, a ... 24mm lens. This is the third new machine vision lens Schneider has introduced in 2009. ...
    ... under-represented in clinical cancer research published in high-impact journals, ... University of Michigan Comprehensive Cancer Center. Taking into ... women, studies included a smaller proportion of women than ... of cancer types that were not gender specific, including ...
    ... Perinatology as a Medical Specialty , , WHITE PLAINS, N.Y. ... the United States and worldwide has been seen through the eyes ... evaluate an infant,s health at birth. , , Yesterday marked ... of Dimes, the organization she worked for from 1959 until her ...
    Cached Medicine News:Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 2Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 3Health News:Cox Business Addresses Complex Voice Needs of Health Care Organization 4Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 2Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 3Health News:National Marrowthon Campaign Aims to Bring Nearly 50,000 to the Be The Match Registry(SM) in Two Weeks 4Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 2Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 3Health News:Parents in Missouri Can Now Test Their Children for Lead Exposure Using Saliva 4Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 2Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 3Health News:Schneider Introduces APO-Xenoplan 2.0/24mm Lens, Specially Designed for Kodak 4 MP Sensors Having Microlenses 4Health News:Women under-represented in cancer research, U-M study finds 2Health News:March of Dimes Honors 100th Anniversary of Virginia Apgar 2Health News:March of Dimes Honors 100th Anniversary of Virginia Apgar 3
    ... articulation maintains full inter-changeability. Modular tibial components ... fit. The Maxim Knee system is ... with expanded options to address surgeon preferences ... for use in total knee replacements both ...
    Tibial distractor...
    Simple, stable knee positioning triangles for lower extremity surgery. The triangles are radiolucent, autoclavable, and use latex-free, sterile, disposable pads....
    ... Cemex features a unique self-contained ... clinically proven in Europe for ... integrating bone cement powder and ... system, Cemex is designed to ...
    Medicine Products: